top of page


Canals I, Comella-Bolla A, Cepeda-Prado E, Avaliani N, Crowe JA, Oburoglu L, Bruzelius A, King N, Pajares MA, Pérez-Sala D, Heuer A, Rylander Ottosson D, Soriano J, Ahlenius H. Astrocyte dysfunction and neuronal network hyperactivity in a CRISPR engineered pluripotent stem cell model of frontotemporal dementia. Brain Communications. 2023. doi: 10.1093/braincomms/fcad158.

Giacomoni J, Habekost M, Cepeda-Prado E, Mattsson B, Ottosson DR, Parmar M, Kajtez J. Protocol for optical clearing and imaging of fluorescently labeled ex vivo rat brain slices. STAR Protoc. 2023 Jan 18;4(1):102041. doi: 10.1016/j.xpro.2022.102041. 

Sozzi E, Kajtez J, Bruzelius A, Wesseler MF, Nilsson F, Birtele M, Larsen NB, Ottosson DR, Storm P, Parmar M, Fiorenzano A. Silk scaffolding drives self-assembly of functional and mature human brain organoids. Front Cell Dev Biol. 2022 Oct 14;10:1023279. doi: 10.3389/fcell.2022.1023279. 

Birtele M, Storm P, Sharma Y, Kajtez J, Wahlestedt JN, Sozzi E, Nilsson F, Stott S, He XL, Mattsson B, Ottosson DR, Barker RA, Fiorenzano A, Parmar M. Single-cell transcriptional and functional analysis of dopaminergic neurons in organoid-like cultures derived from human fetal midbrain. Development. 2022 Oct 28:dev.200504. doi: 10.1242/dev.200504.

Drouin-Ouellet J, Legault EM, Nilsson F, Pircs K, Bouquety J, Petit F, Shrigley S, Birtele M, Pereira M, Storm P, Sharma Y, Bruzelius A, Vuono R, Kele M, Stoker TB, Ottosson DR, Falk A, Jakobsson J, Barker RA, Parmar M. Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson's disease. Stem Cell Reports. 2022 Oct 11;17(10):2203-2219. doi: 10.1016/j.stemcr.2022.08.010. 

Kajtez J, Wesseler MF, Birtele M, Khorasgani FR, Rylander Ottosson D, Heiskanen A, Kamperman T, Leijten J, Martínez-Serrano A, Larsen NB, Angelini TE, Parmar M, Lind JU, Emnéus J. Embedded 3D Printing in Self-Healing Annealable Composites for Precise Patterning of Functionally Mature Human Neural Constructs. Adv Sci (Weinh). 2022 Sep;9(25):e2201392. doi: 10.1002/advs.202201392. 


Fiorenzano A, Sozzi E, Birtele M, Kajtez J, Giacomoni J, Nilsson F, Bruzelius A, Sharma Y, Zhang Y, Mattsson B, Emnéus J, Ottosson DR, Storm P, Parmar M. Single-cell transcriptomics captures features of human midbrain development and dopamine neuron diversity in brain organoids. Nat Commun. 2021 Dec 15;12(1):7302. doi: 10.1038/s41467-021-27464-5. 


Bruzelius A, Kidnapillai S, Drouin-Ouellet J, Stoker T, Barker RA, Rylander Ottosson D. Reprogramming Human Adult Fibroblasts into GABAergic Interneurons. Cells. 2021; 10(12):3450.

Kidnapillai S, Ottosson DR. Functional Assessment of Direct Reprogrammed Neurons In Vitro and In Vivo. Methods Mol Biol. 2021;2352:183-199. doi: 10.1007/978-1-0716-1601-7_13.

Rylander Ottosson D, Grade S and Heuer A. Editorial: Regeneration and Brain Repair. Front. Cell. Neurosci.2021;15:687992.

doi: 10.3389/fncel.2021.687992

Shrigley S, Nilsson F, Mattsson B, Fiorenzano A, Mudannayake J, Bruzelius A, Ottosson DR, Björklund A, Hoban DB, Parmar M. Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA
Model of Parkinson’s Disease. Journal of Parkinson's Disease, 2020 Preprint:1-14. doi:10.3233/JPD-202366

Giacomoni J, Bruzelius A, Stamouli Christina-Anastasia and Rylander Ottosson D. Direct conversion of Human Stem cell-derived Glial Progenitor Cells into GABAergic Interneurons. Cells, 2020; 9 (11); 2451.

Nolbrant S, Giacomoni J, Hoban D.B, Bruzelius A, Birtele M, Chandler-Militello D, Pereira M, Rylander Ottosson D, Goldman S.A and Parmar M. Direct Reprogramming of Human Fetal- and Stem-cell derived Glial Progenitor Cells into Midbrain Dopaminergic Neurons. Stem Cell Reports, 2020; (15); 1-14.

Pereira M, Birtele M and Rylander Ottosson D. In vivo direct reprogramming of resident glial cells into interneurons by intracerebral injection of viral vectors. Journal of Visual Experiments, 2019; Jun 17(148).

Pereira M, Birtele M and Rylander Ottosson D. Conversion of resident glia into interneurons and their potential for cell therapy. Cellular and Molecular Life Sciences 2019.

Birtele B, Sharma Y, Kidnapillai S, Lau S, Stoker T.B., Barker R.A., Rylander Ottosson D, Drouin‐Ouellet J, Parmar M. Dual modulation of neuron-specific microRNA and the REST complex promotes functional maturation of human adult induced neurons. Federation of European Biochemical Society letters, 2019; 593 (23); 3370-3380.

Pircs K, Petri R, Madsen S, Brattas PL, Vuono R, Rylander Ottosson D, St-Amour I, Hersbach BA, Matusiak-Bruckner M, Lundh SH, Petersen A, Deglon N, Hebert SS, Parmar M, Barker RA, Jakobsson J. Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. Cell Reports, 2018: 24: 1397-406.

Pereira M, Birtele M, Shrigley S, Benitez JA, Hedlund E, Parmar M, Ottosson DR. Direct Reprogramming of Resident NG2 Glia into Neurons with Properties of Fast-Spiking Parvalbumin-Containing Interneurons. Stem Cell Reports. 2017 Sep 12;9(3):742-751. doi: 10.1016/j.stemcr.2017.07.023. 

Ruetz T, Pfisterer U, Di Stefano B, Ashmore J, Beiazza M, R Manning J, Chantzoura E, Rylander Ottosson D, V. Tian T, Johnsson A, Cohen E, Yusa K, Linnarsson S, Graf T, Parmar M and Kaji K. A general transcription co-factor, smad3, potentiates master transcription factor mediated cell identity conversions. Cell Stem Cell, 2017: 21 (6), 591-805.

Aldrin-Kirk P, Heuer A, Rylander Ottosson D, Davidsson M, Mattsson B, Björklund T. Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum. Neurobiology of Disease, 2018: 109, 148-162.

Drouin-Ouellet J, Lau S, Ludvik Brattås P, Rylander Ottosson D, Pircs K, Grassi D.A, M Collins L, Vuono R, Andersson Sjöland A, Westergren-Thorsson G, Graff C, Minthon L, Toresson H, A Barker R, Jakobsson J & Parmar M. REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways Embo. Molecular Medicine 2017:9 (11), 17-1131

Kirkeby A, Nolbrant S, Tiklova K, Heuer A, Kee N, Cardoso T, Rylander Ottosson D, Lelos M, Rifes P, Dunnett S, Grealish S, Perlmann T and Parmar M. Identifying markers predicting successful graft outcome for clinical translation of hESC-based cell therapy for Parkinson’s disease. Cell Stem Cell, 2017; 20:135-148.

Torper O, Rylander Ottosson D, Pereira M, Lau S, Cardoso T, Parmar M. In Vivo Reprogramming of Striatal NG2 Glia into Functional Neurons that Integrate into Local Host Circuitry. Cell Reports, 2015; 12: 474-81

Lau S, Rylander Ottosson D, Jakobsson J, Parmar M. Direct neural conversion from human fibroblasts using self-regulating and non-integrating viral vectors. Cell Reports, 2014; 9:1-8.

Pereira M, Pfisterer U, Rylander D, Torper O, Lau S, Lundblad M, Grealish S, Parmar M. Highly efficient generation of transplantable induced neurons from human fibroblasts. Scientific Reports, 2014: 4:6330.

Rylander D, Bagetta V, Pendolino V, Marinucci S, Zianni E, Grealish S, Fabrizio G, Di Luca M, Calabresi P Cenci M.A. and Picconi B. Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism. Preceedings of the National Accademy of Science, 2013; 46:4375-84.

Iderberg H, Rylander D, Cenci MA. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Experimental. Neurology, 2013: 250:116-24.

Lindgren HS, Rylander D, Iderberg H, Andersson M, O'Sullivan SS, Williams DR, Lees AJ, Cenci MA. Putaminal Upregulation of FosB/ FosB-Like Immunoreactivity in Parkinson’s Disease Patients with Dyskinesia. Journal of Parkinson's Disease, 2011.

Rylander D, Parent M, O'Sullivan SS, Dovero S, Lees AJ, Bezard E, Descarries L, Cenci MA. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Annals of Neurology: 2010: 68:619-628.

Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiology of Disease, 2010 39:352-361.

Malmlof T, Rylander D, Alken RG, Schneider F, Svensson TH, Cenci MA, Schilstrom B Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Experimental Neurology, 2010: 225:408-415.

Schuster, S., Doudnikoff E, Rylander D, A. Berthet, I. Aubert, C. Ittrich, B. Bloch, M. A. Cenci, D. J. Surmeier, B. Hengerer and E. Bezard. "Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia." Biological Psychiatry, 2009: 65 (6), 518-526.

Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. Journal of Pharmacology and Experimental Therapeutics, 2009: 330: 227-35

Lindgren H, Rylander D, Ohlin K.E, Lundblad M, Cenci M.A. The ”motor complication syndrome” in rats with 6-OHDA lesions treated chronically with L-DOPA: Relation to dose and route of administration. Behavioural Brain Research. 2007: 177 (1): 150-159.

bottom of page